Inhibrx (INBX)

• Market cap: $177M
• 1 day: 2.34%
• 5 days: 8.88%
• 1 month: -13.78%
• 3 months: -1.21%
• 6 months: -20.23%
• Year to date: -19.61%
• 1 year: -28.76%
• 5 years: -28.76%
• 10 years: -28.76%
• Sector: Healthcare
• Industry: Biotechnology

About: Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Employees: 161

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

206% more call options, than puts

Call options by funds: $1.28M | Put options by funds: $418K

55% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 11

23% more capital invested

Capital invested by funds: $139M [Q3] → $172M (+$32.5M) [Q4]

15.64% more ownership

Funds ownership: 61.45% [Q3] → 77.09% (+15.64%) [Q4]

4% more funds holding

Funds holding: 96 [Q3] → 100 (+4) [Q4]

3% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 29